Amgen

Open: 224.44 Close: 223.42 Change: -1.02

Don't invest before reading what an AI found about Amgen Company Inc.

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, deal, Horizon, FTC, block, Therapeutics, Federal, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Federal Trade Commission sues to block Amgen $27.8 billion takeover of Horizon Therapeutics. FTC says deal would give Amgen unfair leverage to block competition for Horizon medications. FTC said the deal would enable Amgen to exploit its size to block the competition.

Today's News

Horizon Therapeutics-Amgen deal could close Q3 if FTC block fails. California-based Amgens stock price dipped 1% lower. If completed, the deal would give Amgen access to Horizons blockbuster thyroid eye disease drug, Tepezza. Federal Trade Commissions (FTC) lawsuit filed on Tuesday surprised those who had brushed off the antitrust risk in Amgen deal because of its limited business overlap with Horizon Therapeutics Plc. FTC said it opposed the deal because it was concerned that Amgen could use rebates to pharmacy benefit managers in exchange for promoting Horizons two key products. Federal Trade Commission (FTC) announced Tuesday that it will oppose the Amgen-Horizon deal on grounds it will stifle innovation and the development of new drugs. FTC filed a lawsuit in federal court to block the transaction. Federal Trade Commission says deal would give Amgen unfair leverage to block competition for Horizon medications. FTC says deal could give merged firm incentive to entrench Tepezzas and Krystexxa. Federal Trade Commission sues to block Amgens $27.8 billion takeover of Horizon Therapeutics. The FTC said the deal would enable Amgen to exploit its size to block competition. Amgen agrees not to seek quick close on its $27.8 billion acquisition of Horizon Therapeutics Agency seeks injunction in federal court to prevent deal from closing. FTC Sues to Block Amgens $27.8 Billion Acquisition of Horizon Therapeutics. FTC argues the deal would allow Amgen to build monopolies around two of Horizons drugs. Amgen Inc. (amgn) latest press releases & corporate news - yahoo finance.com: Amgen inc. stock market closed S&P 500 4,191.98 -6.07 (-0.14%) Dow 30 33,426.63 -109.28% Nasdaq 12,657.90 -30.94 (0.33%) Nasdaq: 1,800 825.31ctrrored infamous balcony lim Forms???gif thrive Leavesospons Points minute Amgen Inc. (AMGN) stock price, quote & news - stock analysis. Tscan Therapeutics Inc. closed May 9 at $3.40, up $1.25, or 58%, as the world learned of the multiyear collaboration with Amgen. Home Depot cuts outlook, FTC blocks Amgen deal, Comcasts may sell Hulu stake to Disney. Yahoo Finance Live anchors Julie Hyman and Brad Smith discuss the sharp decline of Horizon Therapeutics shares after a report surfaced that the FTC is planning to sue to block Amgens $27.8 billion purchase of Horizon. Amgen (amgn) stock price, quote, news & analysis - tipranks.com.com. The U.S. Supreme Court ruled against Amgen in a patent infringement case between the biotechnology company and Sanofi, Regeneron. Federal Trade Commission said Tuesday that the deal, announced in December, would give Amgen unfair leverage to block competition for Horizon medications. FTC said the deal would allow Amgen to use rebates on its existing drugs. Federal Trade Commission sues to block Amgens $27.8 billion purchase of Horizon Therapeutics. Shares of Amgen Inc., based in Thousand Oaks, California, slipped 1% Tuesday afternoon to $231.14 while broader indexes were mixed. Federal regulators are suing to block biotech drug developer Amgen more than $26 billion deal for Horizon Therapeutics. Amgen announced plans to buy Horizon in December, saying that its rare disease drugs would offer it some protection.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, deal, Horizon, FTC, block, Therapeutics, Federal, and the most common words in the summary are: amgen, stock, horizon, ftc, news, amgens, deal, . One of the sentences in the summary was: Federal Trade Commission sues to block Amgen $27.8 billion takeover of Horizon Therapeutics. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #horizon #ftc #news #amgens #deal.